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The viral oncoprotein E6 is an essential factor for
cervical cancers induced by ‘‘high-risk’’ mucosal
HPV. Among other oncogenic activities, E6 recruits
the ubiquitin ligase E6AP to promote the ubiquitina-
tion and subsequent proteasomal degradation of
p53. E6 is prone to self-association, which long
precluded its structural analysis. Here we found
that E6 specifically dimerizes through its N-terminal
domain and that disruption of the dimer interface
strongly increases E6 solubility. This allowed us
to raise structural data covering the entire HPV16
E6 protein, including the high-resolution NMR
structures of the two zinc-binding domains of E6
and a robust data-driven model structure of the
N-terminal domain homodimer. Interestingly, homo-
dimer interfacemutations that disrupt E6 self-associ-
ation also inactivate E6-mediated p53 degradation.
These data suggest that E6 needs to self-associate
via its N-terminal domain to promote the polyubiqui-
tination of p53 by E6AP.
INTRODUCTION
Human papillomaviruses (HPVs) are small DNA viruses that
induce squamous epithelial neoplasia. Over 120 HPV types
have been identified featuring distinct tropisms for different
body sites (skin, mouth, and genitalia) (de Villiers et al., 2004).
HPVs can be divided into ‘‘low-risk’’ and ‘‘high-risk’’ types
according to the propensity of the lesions to evolve into malig-
nancies. ‘‘High-risk’’ mucosal HPVs are the causative agents of
cervical cancers, with HPV16 and HPV18 being the most
common oncogenic types associated with 50% and 20% of
the carcinomas, respectively (Bosch et al., 1995). In HPV-
positive cervical carcinomas, two viral genes, E6 and E7, are
expressed and act cooperatively to promote tumorigenesis.
The HPV E6 oncoprotein interacts with several cellular proteins,
thereby activating a number of oncogenic pathways that lead
to blockage of apoptosis, alterations of the transcription604 Structure 20, 604–617, April 4, 2012 ª2012 Elsevier Ltd All rightsmachinery, interference with cell-cell interactions and cell
immortalization (Chakrabarti and Krishna, 2003). One of the
most investigated oncogenic activities of ‘‘high-risk’’ mucosal
HPV E6 proteins is the ability to inactivate the tumor suppressor
p53 by targeting it to degradation (Werness et al., 1990). E6 has
been found to recruit the E3 ubiquitin ligase E6AP (Huibregtse
et al., 1991; Scheffner et al., 1993) by binding to a conserved
LXXLL motif located in a presumably natively unfolded region
of the ligase (Chen et al., 1998; Huibregtse et al., 1993). This
binding event alters E6AP substrate specificity via an unknown
mechanism that allows recruitment and polyubiquitination of
p53, which is subsequently degraded by the 26S proteasome
(Scheffner et al., 1995). In addition to p53, other host cell proteins
are recruited and sometimes targeted for ubiquitin-mediated
degradation by ‘‘high-risk’’ mucosal HPV E6. Among these
targets are proteins containing multiple PDZ domains that bind
to the C terminus of E6, which include the tumor suppressor
human discs large (hDlg) (Kiyono et al., 1997) and the MAGI
family of proteins (Glaunsinger et al., 2000; Thomas et al.,
2002), the proapoptotic protein Bak (Thomas and Banks, 1998)
and c-Myc (Gross-Mesilaty et al., 1998). Recent studies suggest
that additional E6 mediated p53 degradation pathways might
exist that are independent of E6AP ligase activity (Camus
et al., 2007; Massimi et al., 2008; Nomine´ et al., 2006; Shai
et al., 2007). In addition, putative mechanisms modulating
E6-mediated degradation have been proposed, which include
proteasome-mediated degradation of both E6 (Stewart et al.,
2004) and E6AP (Kao et al., 2000), stabilization of E6 by E6AP
(Tomaic et al., 2009), E6 interaction with the deubiquitinating
enzyme USP15 (Vos et al., 2009), and inhibition of the E6/E6AP
activity by the EDD ubiquitin ligase (Tomaic et al., 2011).
HPV E6 proteins are rather small in size (about 150 amino
acids) and share a common architecture consisting of two
zinc-binding domains (E6N and E6C) (Nomine´ et al., 2003). For
HPV16 the E6N domain undergoes homodimerization (Lipari
et al., 2001), whereas the E6C domain remains monomeric at
high concentrations (Nomine´ et al., 2005). We and others have
observed that E6 proteins from different phylogenetic viral
groups undergo self-association in vitro (Garcı´a-Alai et al.,
2007; Nomine´ et al., 2001b; Zanier et al., 2007), generating
oligomeric species with native-like properties with respect to
domain folds and activities (Zanier et al., 2010) and in vivo
upon transfection in eukaryotic cells (Garcı´a-Alai et al., 2007;reserved
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a long time precluded structural work on this oncoprotein.
Consequently, to date the structural data available on E6
proteins is limited to one single NMR structure, describing the
E6C domain of HPV16 (Nomine´ et al., 2006).
In this work, we raised high-resolution structural data covering
the entire HPV16 E6 protein by solving the NMR structure of
the E6N domain, calculating a data-driven model of the E6N
homodimer and revisiting the NMR structure of the E6C domain.
Site-directed mutagenesis at the E6N homodimer interface
revealed by the structures strongly suggests that E6 self-associ-
ation mediated by the E6N region is necessary in the process of
p53 degradation.
RESULTS
Characterization of the E6N Homodimer
The HPV16 E6N domain (residues 1–80) was expressed and
purified according to the protocols developed for E6 proteins
(Zanier et al., 2007). 1H,15N-HSQC NMR spectra were acquired
on the E6N domain at concentrations ranging between
300 mM, which is the maximal concentration attained by this
construct, and 25 mM. Spectra comparison shows that amide
groups belonging to residues H24, E41, Y43, D44, and F47 expe-
rience significant chemical shift displacements upon dilution
(>60 Hz) (Figure 1A). In parallel, analytical ultracentrifugation
velocity experiments reveals the existence of monomeric and
dimeric species in samples of the E6N domain (Figure 1B, black
line). By contrast, a mutated E6N domain bearing the F47R
substitution turns out to be monomeric in ultracentrifugation
experiments (Figure 1B, red line). We thus fitted the chemical
shift perturbation data of the wild-type domain to the standard
equation for monomer-dimer equilibrium, yielding an equilibrium
dissociation constant (KD) of 290 ± 120 mM (Figure 1C). Com-
parable monomer-dimer affinity values have been obtained
from equilibrium ultracentrifugation experiments for a similar
construct of HPV16 E6N (Lipari et al., 2001).
Next, we applied standard triple resonance NMR methods to
fully assign backbone and side-chain resonances of wild-type
E6N both at 150 and 300 mM concentrations, as well as those
of the monomeric E6N F47R construct. The similarities of the
1H,15N-HSQC spectra and of the secondary carbon chemical
shift values of wild-type and E6N F47R indicate that the two
constructs have very similar structures (Figures S1A and S1B
available online). The differences in composite 1H, 13C, and 15N
chemical shifts were then computed, either between diluted
and concentrated wt E6N or between concentrated wt E6N
and E6N F47R (Figure 1D). The resulting profiles are remarkably
similar, showing that the mutation destabilizes dimerization
similarly to dilution, without altering the conformation of the
domain. This allowed us to precisely identify the residues at the
dimer interface: I23, H24, R39, R40, E41, Y43,D44, A46, andF47.
NMR Structures of E6N and E6C Domains
Line-broadening phenomena likely resulting from transient
dimerization of the HPV16 E6N domain significantly affect the
quality of the NMR spectra. By contrast, the monomeric E6N
F47Rmutant is an optimal target for structure determination, dis-
playing improved line-widths (Figure S1C). We therefore pro-Structure 20ceeded to determine the solution structure of the monomeric
E6N F47R mutant domain. In addition, we applied triple reso-
nance NMR to revisit the structure of the monomeric HPV16
E6C 4C/4S mutant domain (residues 80–151), which had been
previously solved using only homonuclear and double resonance
NMR (Nomine´ et al., 2006). Thanks to the 13C-editing we were
now able to correct the assignments of a small number of
side-chain resonances of the E6C 4C/4S construct.
The resulting structures are well-defined with an average of 15
and 19 Nuclear Overhauser Effect (NOE) restraints per residues
for the E6N and E6C domains respectively (Table 1). The pair-
wise rmsd for backbone atoms of residues 12–71 of the E6N
domain is 0.82 A˚, while residues 72–80, comprising the interdo-
main linker, are unstructured (Figure 2A). Similarly the E6C
domain has residues 80–143 well-defined with a backbone
rmsd of 0.56 A˚ and the C-terminal residues 144–151 unstruc-
tured (Figure 2B). Noteworthily, the structures reveal that the
F47R substitution and the four cysteine-serine mutations are
all directed at solvent exposed residues (see Figure 3B), further
reinforcing the view that these mutations do not alter the confor-
mation of the domains.
The overall fold of the E6C domain remains as previously
described except a few modifications in the positioning of
secondary structure elements (Figure S2). These modifications
do not alter the surface properties of the domain, which were
the main feature put forward in our former analysis of this
construct (Nomine´ et al., 2006) (see below for further discussion).
The E6N fold consists of a three-stranded b sheet and three
a helices. The zinc-binding site is peripheral with two liganded
cysteines contributed by a knuckle, which provides one strand
(b1) to the b sheet, and the other two situated in the C-terminal
helix. The N-terminal region, corresponding to residues 1–10,
adopts an extended and rather flexible structure as indicated
by the low 1H-15N heteronuclear NOE values, which correlate
with dynamic events in the nanosecond timescale. Such dyn-
amic properties are reflected in the poorer definition in the
NMR ensemble, as shown by the larger backbone rmsds (Fig-
ure 3A). However, in spite of the backbone flexibility, we could
observe long-range NOE contacts between the aromatic
protons of F2 and the side chains of core residues P9, L15,
L19, Y54, and P59. These constraints place the aromatic ring
of F2 in a well-defined position, anchoring the flexible N-terminal
region to the hydrophobic core (Figure 3A).
The structures of the HPV16 E6N and E6C domains are homol-
ogous with the exception of the N-terminal regions (Figure 3B).
Whereas the N-terminal region of E6N is a flexible loop, the N
terminus of E6C (residues 80–84) folds into an additional
b strand (b0), which extends the b sheet. In spite of the structural
homology, the surface properties of the two domains differ (Fig-
ure S3).While the E6N domain has both acidic and basic regions,
the E6C domain is mostly positively charged. Concerning
surface hydrophobicity, we observe two distinct hydrophobic
regions at opposing sides of E6N, one corresponding to residues
located on the b2 strand, the zinc-binding hairpin and helix a3,
the other one mostly consisting of the E6N homodimerization
surface discussed below (Figure S3A). For E6C, exposed hydro-
phobic residues cluster within a unique region as previously
described by Nomine´ et al. (compare Figure S3B and Figure 1
in Nomine´ et al., [2006])., 604–617, April 4, 2012 ª2012 Elsevier Ltd All rights reserved 605
Figure 1. Dimerization of the HPV16 E6N Domain
(A) Superimposition of a region of the 1H-15N HSQC spectra of the wild-type HPV16 E6N domain measured at concentrations of 25 (red), 50 (magenta),
100 (violet), 200 (blue), and 300 (black) mM. Amide groups undergoing significant shifts are labeled.
(B) Molecular weight distribution of wild-type and F47R HPV16 E6N constructs derived from sedimentation velocity ultracentrifugation experiments. The
molecular weights of E6N monomeric (E6N) and dimeric ((E6N)2) species are indicated. C(M) indicates arbitrary units.
(C) Estimation of the equilibrium affinity constant (KD) of wild-type HPV16 E6N dimerization. The sum of the chemical shift changes from four selected amide
cross-peaks (belonging to residues H24, E41, D44, F47) are plotted against the total concentration of the E6N domain. Dd = (10*(dH-dH0)
2 + ((dN-dN0)
2)1/2 where
dH and dN are the proton and nitrogen chemical shifts of each residue, while dH0 and dN0 are the proton and nitrogen chemical shifts at 25 mM. The KD value
derived from the fit corresponds to 290 ± 120 mM.
(D) Chemical shift perturbations induced by dilution of the wt E6N sample (wt E6N at 300 mM versus 150 mM) (top plot) and introduction of the F47R mutation
(corresponding to chemical shift differences between wtE6N at 300 mM versus E6N F47R) (bottom plot). The y axis of the lower plot has been inverted for clarity.
Dd is a composite shift obtained by combining on a per-residue basis the chemical shift changes for all assigned 1H, 13C and 15N. Composite
Dd= 1=NðPNi =1Dn2i =siÞ2 whereN is the number of nuclei,Dn is the chemical shift displacement and s is the spectral dispersity factor of each nucleus derived from
the BMRB data bank. Residues undergoing chemical shift displacementsR0.0075 ppm upon wt E6N dilution orR0.050 ppm upon introduction of the F47R
mutation are indicated. Secondary structure elements are derived from the 3D structure of the E6N F47R domain (see Figure 2). The color coding of secondary
structure elements will be retained in subsequent figures.
See also Figure S1.
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We proceeded to investigate the assembly of the HPV16 E6N
homodimer using the HADDOCK software (Dominguez et al.,606 Structure 20, 604–617, April 4, 2012 ª2012 Elsevier Ltd All rights2003). Ambiguous interaction restraints (AIRs) defined from
chemical shift perturbation data were used to calculate a first
set of E6N homodimer models. Subsequently, we analyzedreserved
Table 1. NMR and Refinement Statistics for the E6N and E6C
Domain Structures
E6N E6C
Restraints for final calculation
Total NOE 1,274 1,464
Intraresidue 433 370
Interresidue
Sequential (ji – jj = 1) 311 366
Medium-range (ji – jj < 5) 240 357
Long range (ji – jj > 5) 290 371
Hydrogen bonds 7 2
Total dihedral angle
restraints (f, c)
87 92
Structure statistics
Rmsds from idealized
geometry
Bonds (A˚) 0.017 ± 0.001 0.017 ± 0.001
Bond angles () 1.880 ± 0.050 2.160 ± 0.050
Impropers () 1.790 ± 0.080 1.980 ± 0.080
NOE restraints (A˚) 0.045 ± 0.001 0.043 ± 0.001
Dihedral angle restraints () 0.510 ± 0.130 0.490 ± 0.050
Violationsa
Max. dihedral angle
violation ()
4.80 3.54
Max. NOE violation (A˚) 0.39 0.47
Ramachandran plotb
Residues in most favorable
regions (%)
80.5 78.0
Residues in additional
favorable regions (%)
16.8 21.0
Residues in generously
favorable regions (%)
0.5 0.7
Residues in disallowed
regions (%)
2.2 0.4
Coordinate precisionb
Average pairwise rmsd (A˚)c
Heavy 1.48 ± 0.19 1.13 ± 0.15
Backbone 0.82 ± 0.14 0.56 ± 0.14
Statistics are given for the 20 lowest-energy structures after water refine-
ment out of 100.
aNo distance restraint was violated by >0.5 A˚ and no dihedral angle
restraint by >5.
bCalculated for residues 12–72 (E6N) and residues 80–143 (E6C).
cPairwise rmsds were calculated using MOLMOL (Koradi et al., 1996).
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E6 Self-Association Required for p53 Degradationwild-type E6N NOESY spectra acquired at different concentra-
tions. This allowed us to identify 11 unambiguous intermolecular
NOEs that were consistent with the best scoring cluster of homo-
dimermodels. All intermolecular NOEs originate from contacts of
the aromatic protons of F47 with protons from residues I23, H24,
and Y43 (Figure S4A). Hence, intermolecular NOE-derived
distance restraints were combined with AIRs to calculate a final
set of E6N homodimer model structures that were grouped into
three clusters, all fulfilling equally well the NMR data and display-
ing similar subunit arrangements (Figures S4B and S4C). TheStructure 20top-scoring cluster (cluster 1) contains the 65%of the structures.
Statistics for the 20 best models in cluster 1 are reported in
Table 2.
The homodimer interface corresponds to helix a2 and the loop
region between helix1 and the zinc knuckle. In all models calcu-
lated F47 appears to dominate the homodimer interface, with its
aromatic ring lying in a shallow hydrophobic cavity made of resi-
dues I23, H24, Y43, A46, and F47 of the opposing subunit (Fig-
ure 4A). In some of the structures, the side chains of arginine and
aspartic acid residues at the homodimer interface engage in both
intra- (R48/D44) and intermolecular (R39/D64) ionic bridges (Fig-
ure 4A). Although poorly defined in the structure ensemble due
to the lack of NOEs, these ionic interactions are consistent with
the observation of a larger extent of protection of arginine side-
chain exchangeable protons in the NMR spectra of the wt E6N
homodimer compared to the E6N F47R monomer (Figure S4D).
Alignment of E6N sequences from different phylogenetic
PV groups shows that the hydrophobic/aromatic character of
residues I23, Y43, and F47 participating in key intermolecular in-
teractions is conserved in both ‘‘high-risk’’ and ‘‘low-risk’’
mucosal HPV strains from the A9, A7, and A10 species, while
most charged and polar residues (R39, R40, D44, and D64) of
the interface are less conserved, with the exception of E41 that
is strictly conserved in all papillomaviruses, probably due to its
structural role (helix capping for a3) (Figure 4B). To further inves-
tigate conservation of E6N dimerization, we analyzed samples of
E6N domains issued from different groups. The isolated E6N
domains from HPV18, HPV5, and BPV1 strains could be purified
at high concentrations and were folded according to the chem-
ical shift dispersion observed in the 1H,15N-HSQC spectra
(data not shown). According to the analytical ultracentrifugation
profiles (Figure 4C, left panel), while the HPV18 E6N domain
(residues 1–82) undergoes dimerization, both theHPV5 (residues
1–91) and BPV1 E6N domains (residues 1–66) are clearly mono-
meric. The HPV11 E6N domain (residues 1–81) was poorly
soluble in isolation. To turn around this problem, we analyzed
this domain as a fusion to the MBP tag, which allowed it to attain
higher concentrations. Analytical gel filtration chromatography of
the HPV11 MBP-E6N construct shows a progressive shift from
a monomeric to a dimeric species with increasing sample con-
centration (Figure 4C, right panel). This latter analysis suggests
an equilibrium affinity of dimerization in the same range as that
of the HPV16 E6N dimer. Therefore these results support the
view that E6N homodimerization is a property of E6 proteins
from both high-risk and low-risk mucosal HPV strains.
Disruption of E6N Dimerization Decreases
Self-Association of Full-Length E6
We were interested in probing the role of the E6N dimerization
region with respect to the self-association of full-length E6. For
this purpose, we generated a panel of E6N constructs that, like
E6N F47R, bear single-point mutations at the dimer interface
(H24A, Y43R, Y43E, D44A, D44R, and F47E). All constructs
were folded according to the 1H,15N-HSQC spectra (data not
shown). E6Nmutants were then submitted to analytical ultracen-
trifugation velocity experiments (Figure 5A). As expected, all
mutations turn out to weaken dimerization. Substitutions of
Y43 and F47 with both arginine and glutamic acid disrupt dimer-
ization, in agreement with the hydrophobic role of these residues, 604–617, April 4, 2012 ª2012 Elsevier Ltd All rights reserved 607
Figure 2. NMR Ensembles of the E6 Domain
Structures
Stereo views of the 20 lowest energy structures of E6N
F47R (residues 1–71) (A) and E6C 4C/4S (residues 80–143)
(B). Zinc atoms are represented as gray spheres. Figures
of the molecular structures were made using PyMOL
(DeLano, W.L. The PyMOL Molecular Graphics System
DeLano Scientific, San Carlos, CA).
See also Figure S2.
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E6 Self-Association Required for p53 Degradationrevealed by the dimer structures. However, the peaks of the
F47E and Y43E mutants are shifted toward higher molecular
weight compared to those of the arginine substitutions, reflect-
ing the existence of residual monomer-dimer equilibrium and
therefore a lower efficiency of glutamic acid in disrupting dimer-
ization. Similarly the D44R mutation destabilizes the dimeric
state more efficiently than D44A. These latter observations indi-
cate the existence of ionic interactions at the dimer interface,
which is also suggested by the structural data.
Next, we introduced E6N dimer destabilizing mutations in the
context of a mutant of HPV16 E6, named E6 4C/4S, which bears
the same four cysteine-serine substitutions as the E6C domain
used for structure determination. Whereas wild-type HPV16 E6
cannot be purified due to extensive intermolecular disulfide
crosslinking (Nomine´ et al., 2001a), E6 4C/4S is amenable to
purification. Moreover, E6 4C/4S retains a p53 degradation608 Structure 20, 604–617, April 4, 2012 ª2012 Elsevier Ltd All rights reservedactivity profile very similar to that of HPV16 wt
E6 (Figure S5A). The concentration thresholds
of E6 4C/4S constructs bearing E6N dimer-
destabilizing mutations were then determined
by concentrating purified samples of the con-
structs to their solubility limit (Figure 5B). All
E6N dimer mutations were found to enhance
the solubility of E6 4C/4S, although to a different
extent. While only a moderate enhancement is
observed for the Y43R and D44R mutations,
F47 mutations greatly increase E6 solubility,
with the arginine beingmore efficient than gluta-
mic acid as already observed for E6N dimeriza-
tion. Further solubilization of E6 is obtained with
the double F47R-Y43E mutation.
NMR Characterization of Monomeric
Full-Length E6
The enhanced solubility of E6 F47R 4C/4S
allowed us to perform NMR analysis of a full-
length HPV E6 protein. Superimposition of the
1H,15N-HSQC spectrum of E6 F47R 4C/4S
onto those of the E6N F47R and E6C 4C/4S
domains shows that most amide signals of the
full-length E6 construct overlay with signals in
its separated domains (Figure 5C, left panel),
indicating that the structures of the domains
are preserved in the context of the full-length
protein. By combining this information with
triple resonance backbone experiments, we
could assign approximately 92% of the back-
bone frequencies of the full-length E6 F47R4C/4S construct (Figure 5C, right panel). Most missing reso-
nances correspond to the interdomain linker, which experiences
line broadening likely to result from dynamic processes. T1 and
T2 NMR relaxation experiments were then recorded on a maxi-
mally concentrated sample of E6 F47R 4C/4S (Figure S5B).
This raised a tumbling correlation time (tc) of 13 ± 1.5 ns at
296 K, which is consistent with a 18 kDa protein tumbling as
a rigid monomer. Noteworthily, independent tumbling of E6N
and E6C domains would lead to a correlation time of 6–8 ns,
consistent with the value measured previously for the E6C
4C/4S domain (7.8 ± 1.5 ns at 285 K) (Nomine´ et al., 2005).
Correlation of E6 Self-Association and p53 Degradation
Activities
We have previously reported that the F47R mutation leads to
loss of the p53 degradation activity of HPV16 E6 (Nomine´
Structure
E6 Self-Association Required for p53 Degradationet al., 2006; Ristriani et al., 2009). Here we have extended the
analysis to the other E6N dimerization mutants inserted in the
E6 4C/4S construct and already presented in Figure 5. Consis-
tent with what has been previously reported for the F47R muta-
tion, all mutants have wild-type like binding activities to both
E6AP-peptide and full-length E6AP in GST pull-down assays,
suggesting that the E6N dimerization interface is not implicated
in the recruitment of the ubiquitin ligase (Figure S6A). We then
performed a quantitative analysis of the in vitro p53 degradation
activities of the different mutants by incubating constant
amounts of translated and 35S-labeled p53 with varying amounts
of 35S-labeled E6 translation products. In such assays, E6-
mediated p53 degradation activity is measured by the loss of
intensity of p53 bands. The most active E6 constructs are those,
which can degrade p53 at the lowest E6 amounts. While both
wild-type E6 and E6 4C/4S have comparable activity profiles
(with the 4C/4S construct slightly more active, maybe due to
protection from disulfide crosslinking), all mutations at the E6N
homodimer interface affect p53 degradation albeit at different
extents (Figure 6A; Figure S6B).While D44R and Y43Rmutations
have lower impact, mutations at F47 largely suppress p53 degra-
dation activity. We also performed an in vivo assay that makes
use of co-transfection in human C33A cells followed by double
immunofluorescence with anti-E6 and anti-p53 antibodies (Fig-
ure 6B). The disappearance of the red p53 signal in the green
E6-transfected cells indicates E6-mediated p53 degradation.
In this assay, the in vivo p53 degradation activities of the different
mutants are ranked similarly as the in vitro activities.
Next, we plotted p53 degradation activities as a function of
solubility thresholds for all E6 mutants. Interestingly, we find
a remarkable correlation between these two observables: the
higher the concentration threshold value, the lower the p53
degradation activity (Figure 6C). These observations suggest
that formation of a dimeric or oligomeric species of E6 may be
required for p53 degradation.
DISCUSSION
E6, one of the most studied oncoproteins, has long represented
a challenge for structural biologists. In this work, we adopted
a ‘‘divide, mutate, and conquer’’ approach whereby we not
only separated the two folded domains of E6, but also mutated
them to suppress their self-association properties. This allowed
us to solve high-resolution structures of both E6N and E6C
domains, to raise a robust data-driven model of the E6N homo-
dimer, and to obtain structural information on full-length E6.
The low solubility of E6 proteins was a multifactorial problem.
First, E6 proteins are rich in cysteine residues prone to form inter-
molecular disulfide bridges during purification. This initially drove
us to mutate all non-conserved cysteines, generating the HPV16
E6 6C/6S construct (Nomine´ et al., 2001a) as well as comparable
mutants for other E6 proteins (Zanier et al., 2007). E6 6C/6S
retains the capacity to degrade p53 albeit with lower efficiency
than HPV16 wt E6, whereas E6 4C/4S fully retains the efficiency
of E6wt (Figure S8). This finding is explained by the structure: the
four mutated cysteine residues in E6C 4C/4S are solvent-
exposed, whereas the two nonconserved cysteine residues of
E6N are buried and hence prone to destabilize E6 when mutated
(Figure 2B). Second, as previously suggested by Liu et al. (2009),Structure 20the E6N domain plays a role in E6 aggregation. Here, we charac-
terized the E6N dimer and showed that its disruption greatly
enhances E6 solubility, pointing to E6N dimerization as a key
event for E6 oligomerization/polymerization. Third, E6 probably
captures its target ‘‘LxxLL’’ motifs by means of a hydrophobic
pocket, whichmay promote aggregation of unbound E6. Indeed,
we recently showed that aggregation of Bovine (BPV1) E6 is
eliminated when BPV1 E6 is bound to its target LxxLL peptide
(Ould M’hamed Ould Sidi et al., 2011). Noteworthily, cysteine
mutagenesis did not solubilize BPV-1 E6, and BPV1 E6N does
not dimerize, suggesting that BPV-1 E6 aggregation is mainly
driven by its LxxLL-binding pocket. Conversely, binding of
HPV16 E6 to a peptide containing the LXXLLmotif fromE6AP did
not enhance HPV16 E6 solubility. Therefore, E6 self-association
phenomena are not only due to multiple causes, but also
require distinct remedial strategies depending on the E6 protein
considered.
The two zinc-binding domains of HPV16 E6 have homologous
folds. Both domains contain a derived version of the treble cleft
motif found in a large number of zinc-binding proteins with
diverse functions (de Souza et al., 2010; Grishin, 2001). However,
the first ten residues of E6N adopt an extended and flexible
conformation that is ‘‘anchored’’ to the rest of the domain struc-
ture by the aromatic ring of F2, whereas the corresponding
region in E6C folds into an additional b strand. Early work in
our laboratory showed that antibodies targeting residue F2 of
HPV16 E6 block degradation of p53 (Giovane et al., 1999), while
other studies demonstrated that point mutations at residue F2
abolish recruitment of p53 to the HPV16 E6/E6AP complex
and hence the degradation of p53 (Cooper et al., 2003; Liu
et al., 1999). Thus, the flexible N-terminal region of E6N, and
particularly the anchoring residue F2, appears to be implicated
in p53 degradation mediated by ‘‘high-risk’’ mucosal HPV E6
proteins. Interestingly, the N-terminal region of E6N is the least
conserved part of PV E6 proteins, both in composition and in
length (Figure 4B), suggesting that it may have specialized to
allow targeting of distinct sets of cellular proteins.
Within full-length monomeric E6, the structures of E6N and
E6C domains are preserved and their tumbling is correlated.
How and to which extent both domains interact with each other
in the full-length protein is not yet known. Unfortunately, spectra
of monomeric E6 remained significantly affected by line broad-
ening, preventing the completion of the entire 3D structure. We
previously proposed (Nomine´ et al., 2006) a ‘‘pseudodimeric’’
model of E6, which assumed that E6N and E6C domains would
associate symmetrically via their respective N-terminal b strands
(b0 in E6C). However, the structure of E6N does not contain an
N-terminal b strand. In addition, the chemical shifts of most
amide groups in the N-terminal regions of both domains (indi-
cated by arrows in Figure 5C) are not displaced in the spectrum
of the full-length E6 construct. This suggests that the N termini of
both domains neither change conformation nor interact with
each other in the full-length protein, therefore contradicting the
pseudodimeric model previously proposed.
The E6N homodimer structure together with the mutational
data reveals that key interface interactions are mediated by
F47 that lays in a hydrophobic cavity mainly formed by surface
residues I23, Y43 and F47 of the opposing subunit. The hydro-
phobic/aromatic character of these three residues is conserved, 604–617, April 4, 2012 ª2012 Elsevier Ltd All rights reserved 609
Figure 3. Structure and Dynamic Properties of the Monomeric HPV16 E6 Zinc-Binding Domains
(A) (top panel) Ensemble of the 20 lowest energy structures of E6N F47R. The right hand view shows the anchoring residue F2 and other hydrophobic core
residues displaying NOE contacts with F2. (bottom panel) Heteronuclear NOE (red circles) and average pairwise backbone rmsds (black circles) values for the
E6N F47R domain. Rmsds have been calculated over five residue segments of the primary sequence for the 20 lowest energy NMR structures and error bars
represent standard deviations of the mean. Black stars on the x axis mark proline residues.
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Table 2. Statistics of the Best E6N Homodimer Models
NMR Restraintsa
Ambiguous restraints (AIRs) 16
Intermaolecular NOE-derived unambiguous restraints 22
Total dihedral angle restraints (f, c) 74
Structure statistics
Rmsds from idealized geometryb
AIRs (A˚) 0.14 ± 0.11
NOE restraints (A˚) 0.00 ± 0.01
Dihedral angle restraints () 0.54 ± 0.12
Coordinate precisionc
Average pairwise rmsd (A˚)
Backbone 2.2 ± 0.8
Intermolecular energies after water refinement
Evdw (kcal mol
-1) 35 ± 5
Eelec (kcal mol
-1) 119 ± 43
Buried surface area (A˚) 975 ± 90
Statistics for the 20 best-scoring models in cluster1.
aRestraints have been applied symmetrically to each homodimer subunit.
bNo distance restraint was violated by >0.1 A˚ and no dihedral angle
restraint by >5.
cPairwise rmsds calculated for residues 12–72.
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E6 Self-Association Required for p53 Degradationonly in mucosal HPV E6 sequences (Figure 4B), suggesting that
E6N dimerization is an activity specific to the mucosal HPV
strains rather than a general property of all E6 proteins. Indeed,
E6N domains of ‘‘high-risk’’ mucosal HPVs 16 and 18 (belonging
to twodistinct species) andof low-riskmucosalHPV11were found
to dimerize, whereas the E6N domains of the cutaneous strains
HPV5 and BPV1 (a bovine PV) were found to be monomeric.
In the last part of this work, we have investigated the impor-
tance of E6N homodimerization for E6 activities leading to p53
degradation. Interface mutations disrupted E6N dimerization
and enhanced full-length E6 solubility by favoring its monomeric
state as demonstrated for the E6 F47R 4C/4S construct. Inter-
face mutants displayed unaltered E6AP binding but were found
to be defective for p53 degradation activity. A striking correlation
was observed between the solubility thresholds and the p53
degradation activities for all full-length E6 mutants investigated.
This suggests that a dimeric E6 is required to efficiently catalyze
the degradation of p53. Indeed, we have previously reported on
the F47R mutation at times when E6N dimerization had not been
investigated (Nomine´ et al., 2006; Ristriani et al., 2009; Zanier
et al., 2005). Although able to recruit p53 to the E6/E6AP
complex, E6 F47R was defective for polyubiquitination and
subsequent degradation of p53 (Ristriani et al., 2009). On the
basis of the results presented in this work, together with our
previous findings on the F47R mutant, we therefore propose(B) Structural homology of the E6N and E6C domains. (top panel) Percentage of e
F47R and E6C-4C/4S constructs. The y axis of the E6C plot has been inverted for c
The amino acid sequence of each domain is aligned with the x axis and colo
underligned, while exposure values for nonconserved cysteines are indicated b
sentations of the lowest energy NMR structures of the E6N F47R (left) and E6C 4
displayed.
See also Figure S3.
Structure 20that the enzyme (E6AP) and the substrate (p53) are recruited
onto a symmetric dimer of E6 (Figure 7). In thismodel, the relative
orientations of the p53 and E6AP subunits are different when
bound to the same or different E6 molecules. Only E6AP and
p53 bound to different E6 molecules would then associate in
a way that is sterically compatible with the trans-ubiquitination
event leading to degradation of p53. An interesting implication
of this dimeric model is that its inherent symmetry would allow
for allosteric regulation possibly resulting in enhanced enzymatic
efficiency. This model is in agreement with our observation that
heterologously expressed E6 self-associates in vivo (Zanier
et al., 2010), and it is also supported by data from Kao et al.
(Kao et al., 2000), who detected intermolecular interactions
between E6AP molecules mediated by E6. Further investigation
will be required to precisely address the in vivo role of E6
dimerization.
We have found that low-risk mucosal HPV11 E6, which is
unable to degrade p53, also dimerizes via its E6N domain. Hence
E6N dimerization appears to be a necessary but not sufficient
condition to achieve E6-mediated p53 degradation. Remark-
ably, HPV11 E6 has also been reported to bind to E6AP (Brimer
et al., 2007) and to p53 (Gu et al., 2001; Li and Coffino, 1996;
Thomas and Chiang, 2005). However, these authors also sug-
gested that the interfaces between E6, p53, and E6AP are
probably involving different regions for HPV16 and HPV11 E6
proteins, in a manner that p53 ubiquitination is only proficient
for the HPV16 E6-mediated complexes.
By contrast, it seems that dimerization is not required for the
degradation of all targets of E6. For instance, protein tyrosine
phosphatase H1 (PTP H1) is degraded by E6 via a mechanism
requiring E6AP and the proteasome machinery (Jing et al.,
2007; To¨pffer et al., 2007) and this process is unaffected by
the F47R mutation.
The results presented in this work contribute to the under-
standing of the assembly and mechanisms of E6 ubiquitination
proficient complexes. The fact that the E6 dimerization interface
is required for p53 degradation, but not for all targets of the E6/
E6AP complex, suggests that a proficient E6/E6AP/p53 complex
requires a particular assembly mechanism that will deserve to be
addressed in future structural studies.EXPERIMENTAL PROCEDURES
Preparation of Recombinant HPV E6 Samples
The DNA sequences of E6 constructs for recombinant production were cloned
in the NcoI and KpnI sites of the pETM-41 vector containing an N-terminal
His6-MBP tag followed by a TEV cleavage site.
Overexpression of full-length E6 and E6 domain constructs fused to MBP
was carried out overnight in BL21 DE3 cells at 15C. Uniform 13C/15N isotope
labeling was achieved by supplementing minimal M9 medium (containing
15NH4Cl and
13C6-glucose) with 5% CELTONE-CN medium (CIL Inc.). The
purification protocol described in (Zanier et al., 2007) was supplementedxposure to the solvent of residues in the lowest energy NMR structures of E6N
larity. Numbers on the x axis correspond to the wild-type HPV16 E6 sequence.
red to mark secondary structure elements. Zinc coordinating cysteines are
y arrows. Asterisks indicate sites of mutations. (Lower panel) Ribbon repre-
C/4S (right) constructs. Zinc atoms and coordinating cysteine side chains are
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Figure 4. Model Structure of the HPV16 E6N Homodimer
(A) (left panel) Ribbon representation of the lowest energy structure in cluster 1. (right panel) Views of the homodimer interface. The top representation illustrates
the side-chain orientation of interacting residues. The bottom representation illustrates the positioning of the aromatic ring F47 (violet) in the shallow hydrophobic
pocket (green) within the opposing subunit.
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Figure 5. Mutations at the E6N Homodimer Interface Enhance Full-Length E6 Solubility
(A) Homodimer interface mutations have been introduced in the context of HPV16 E6N domain construct and the resulting samples have been analyzed by
sedimentation velocity ultracentrifugation experiments. The profile of the wild-type domain is reported on each plot for clarity.
(B) Concentrations thresholds of samples of full-length E6 mutants. Homodimer interface mutations have been introduced in the HPV16 E6 4C/4S construct.
(C) 1H, 15N HSQC spectra of the E6 F47R 4C/4S construct. (left panel) Superposition of spectra of E6 F47R 4C/4S (black), E6N F47R (cyan), and E6C 4C/4S (red)
constructs. Magenta arrows indicate amide groups belonging to residues 1–10 and 80–90. (right panel) Annotated 1H, 15NHSQC of E6 F47R 4C/4S. Assignments
are shown in red.
See also Figure S5.
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(GE Healthcare).
Analytical Ultracentrifugation
Sedimentation velocity experiments were done at 4C in a Beckman Optima
XL-A centrifuge fitted with a four-hole AN-60 rotor and double-sector Epon
centerpieces (46 000 rpm). Protein concentrations were adjusted to 70 mM in
20 mM sodium phosphate (pH 6.8), 50 mM NaCl, 2 mM DTT. Sedimentation(B) Alignment of E6N sequences of representative strains from the ‘‘high-risk’’ mu
cutaneous B1A1 group and two BPV strains. Residues reported to undergo the
physicochemical properties as follows: magenta, hydrophobic (W, F, Y, L, I, V, M
cystein (C); cyan, small (G, A, P).
(C) (left panel) Molecular weight distribution of wild-type HPV5, HPV18 and BPV1
experiments. (right panel) Analytical gel filtration chromatography analysis of affi
concentrations indicated and injected on a Superdex 200 10/30 column. The elut
110.4 kDa) species are indicated. The shoulder at 14.1 ml corresponds to MBP
markers are reported on top of the figure. ‘‘1,’’ V0; ‘‘2,’’ ferritin (440 kDa); ‘‘3,’’ m
ovoalbumin (43 kDa); ‘‘6,’’ RNase (13.7 kDa).
See also Figure S4.
Structure 20velocity profiles were collected by monitoring the absorbance signal at
280 nm. Sedimentation coefficient and molecular weight distributions were
analyzed by the C(s) method implemented in the Sedfit software package
(Schuck, 2000).
Analytical Gel Filtration Chromatography
HPV11 MBP-E6N preparations were affinity purified and subject to an
overnight ultracentrifugation step as described in (Zanier et al., 2007). Samplecosal HPV A9 and A7 groups, the low-risk mucosal A10 group, the ‘‘high-risk’’
largest chemical shift variations in Figure 1D are colored according to their
); green, basic (K, R, H); red, acidic (E, D); orange, polar (Q, N, T, S); brown,
E6N domain constructs derived from sedimentation velocity ultracentrifugation
nity purified HPV11 MBP-E6N fusion construct. Samples were adjusted at the
ion volumes of the monomeric (MBP-E6N, 55.2 kDa) and dimeric ((MBP-E6N)2,
arising from residual proteolytic activity in the preparations. Molecular size
ouse immunoglobulin G (150 kDa); ‘‘4,’’ bovine serum albumin (67 kDa); ‘‘5,’’
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Figure 6. p53 Degradation Activities of HPV16 E6 Homodimer Interface Mutants
(A) In vitro p53 degradation reactions employing in vitro translated and 35S-labeled proteins. Assays were performed by incubating 2 ml of 35S p53 translation
product with varying amounts of 35S E6 translation products. In the input control the reaction was stopped immediately after mixing p53 and E6 by addition of
loading buffer. (Left) Partial views of the autoradiographs showing the p53 double band after incubation with different amounts of the E6 mutants. For clarity, the
E6 bands for each of the p53 degradation reactions are shown separately in Figure S6B. Lane 1 (L1): input; L2: 5 ml E6; L3: 2.5 ml E6; L4: 1.25 ml E6; L5: 0.75 ml E6;
L6: 0.37 ml E6. (Right) Plot summarizing the in vitro p53 degradation profiles of the different E6 mutants. The p53 degradation activity is represented as (I0  I) / I0
where I is the intensity of the p53 double band after incubation with E6 while I0 p53 signal in the input lane. Error bars represent standard deviations from three
independent experiments.
(B) Double immunofluorescence of E6 and p53 in C33A cells after transfection with wt E6 or E6 mutants. Observation of p53 and E6 was achieved by incubating
cells first with the anti-p53 antibody and then with the anti-E6 antibody. The disappearance of the red p53 signal in E6 transfected cells displaying a green signal
indicates E6 mediated p53 degradation.
(C) Correlation of p53 degradation activities and solubility thresholds of the different E6 mutants. The (I0 I5 ml) / I0 ratio refers to the in vitro p53 degradation in the
presence of 5 ml of E6.
See also Figure S6.
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E6 Self-Association Required for p53 Degradationconcentrations were adjusted to values ranging from 40 to 800 mM. 100 ml
aliquots were injected on a Superdex 200 10/30 column (GE Healthcare)
equilibrated in 20 mM sodium phosphate (pH 6.8), 400 mM NaCl, 2 mM DTT.
The higher salt concentration was employed to avoid aspecific interaction of
MBP-E6N with the column matrix. The experiments were performed at 10C.
NMR Spectroscopy
NMR experiments were recorded on a Bruker DRX 600 MHz spectrometer
equipped with cryoprobe (unless otherwise stated) at 296 K for the wt and
E6N F47R domains and for the full-length E6 F47R 4C/4S construct and at
283 K for the E6C 4C/4S domain. Buffer composition for the E6N and E6C
domain NMR samples was 20 mM sodium phosphate (pH 6.8), 50 mM NaCl,
2 mM DTT. For the full-length E6 samples the NMR buffer was 20 mM sodium
phosphate (pH 6.8), 200 mM NaCl, 2 mM DTT. Backbone and side-chain
assignments of wt E6N, E6N F47R, and E6C 4C/4S constructs were derived
using triple resonance NMR methods (Sattler et al., 1999). Heteronuclear
1H-15N NOE values for the E6N F47R construct were derived from intensities
measured using the experiment described by Farrow et al. (1994).614 Structure 20, 604–617, April 4, 2012 ª2012 Elsevier Ltd All rightsStructure Calculations of E6 Domains
Structure calculations for the E6N F47R and E6C 4C/4S domains were per-
formed using XPLOR-NIH (Schwieters et al., 2003) and ATNOS/CANDID for
automatic peak picking and NOE assignment (Herrmann et al., 2002a,
2002b). Distance restrains were derived from 2D homonuclear NOESY spectra
with mixing times of 100 ms recorded at 800 (E6N F47R) and 950 (E6C 4C/4S
domain) MHz and from 3D 15N-edited and 15C-edited NOESY spectra
(optimized for aliphatic nuclei) with mixing times of 100 ms. Dihedral angle
restraints for 4 and c angles were derived from Ca and Cb chemical shifts
using the program TALOS (Cornilescu et al., 1999). Hydrogen bond restrains
were derived from slowly exchanging amide protons upon dilution of concen-
trated samples into D2O buffer. Zn-Sg distances were set to 2.4 A˚. The struc-
tures were then refined using parallhdg5.3 parameters (Linge et al., 2003;
Nabuurs et al., 2004) and chirality assignments weremade before water refine-
ment. The final ensembles of 20 conformations for the E6N F47R and E6C
4C/4S domains have no NOE violations greater than 0.5 A˚ and no dihedral
angle violations greater than 5. Ramachandran plot analysis was performed
using PROCHECK (Laskowski et al., 1996).reserved
Figure 7. Putative Model of the E6/E6AP/p53 Trimery Complex
At the center the ribbon representation of a symmetric dimer of E6mediated by
the E6N domains. The two subunits of the dimer are shown in green and violet
respectively. The relative orientation of the E6N and E6C domains is arbitrary.
Each E6 molecule binds to one molecule of E6AP (yellow cartoon) and one
molecule of p53 (pink cartoon). In this model, only ubiquitin transfer events are
possible that originate between E6AP and p53 molecules loaded on different
subunits of the E6 dimer.
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Structure calculations for the E6N homodimer were performed using the
HADDOCK web server (de Vries et al., 2010; Dominguez et al., 2003). Starting
coordinates were the 10 lowest energy NMR structures of E6N F47R, with
each structure in the ensemble back mutated in silico to produce the wild-
type domain. Ambiguous interactions restraints (AIRs) were derived from the
changes in the chemical shifts of assigned 1H, 13C, and 15N resonances.
The approach adopted used initial modeling to guide identification of inter-
molecular NOEs. In a first set of calculations, only AIRs were used during the
docking steps. The resulting models were hierarchically clustered into 5
distinct clusters. Weak intermolecular NOEs were identified from 2D homonu-Structure 20clear NOESY spectra recorded on samples at 300 to 150 mM of wt E6N at 700
MHz with mixing times of 100, 150, and 200 ms. The identified intermolecular
NOEs satisfied the following conditions: (1) they decreased in intensity upon
dilution of the sample, (2) they were consistent with E6N homodimer models
in the top scoring cluster of the HADDOCK calculations and, finally, (3) they
originated from proton pairs separated by more than 8 A˚ in the monomer
structure. In the final calculations AIRs, unambiguous intermolecular
NOE-derived restraints (applied with generous error bounds, i.e., 3.9 ±
2.1 A˚) as well as dihedral angle restraints were enforced during all docking
steps. During the first iteration, 1,000 models were calculated keeping the
domain structure rigid. The 200 lowest energy models were then submitted
to semi-flexible torsion angle simulated annealing in the second iteration and
finally refined in explicit solvent. The final structures were clustered using
a cutoff value of 5 A˚ and aminimum cluster size of 10 structures. The 20 lowest
energy structures from the HADDOCK top-scoring cluster (cluster 1) have no
NOE violations greater than 0.1 A˚ and no dihedral angle violations greater
than 5.
p53 Degradation Assays
HPV16 E6 mutants were cloned in the BamHI and KpnI sites of the pXJ40
vector. In vitro p53 degradation reactions were performed by incubating 2 ml
of 35S p53 translation product with varying amounts (5–0.37 ml) of 35S E6
translation products at 28C for 2 hr according to previously described proto-
cols (Nomine´ et al., 2006). Reactions were analyzed by SDS-PAGE and auto-
radiography. Bands were quantified using a Gel Doc (1,000 UV)XR+ apparatus
(Biorad). In vivo p53 degradation assays were performed by transfecting
human C33A cells with HPV16 E6 mutants as described in (Nomine´ et al.,
2006). Simultaneous observation of p53 and E6 was achieved by incubating
cells first with polyclonal anti-p53 antibody (FL393, Santa Cruz Biotechnology)
and then with monoclonal anti-E6 antibody 6F4 (Masson et al., 2003).
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